From left: Sunkyu Kim, Director at AIGEN Sciences; Jaewoo Kang, CEO of AIGEN Sciences; Zehua Cheng, Chief Scientist at Flock; and Dr. Wei Dai | Photo provided by AIGEN Sciences
Web3-native platform Flock and award-winning AI drug discovery company AIGEN Sciences have signed a Memorandum of Understanding (MOU) to integrate their technologies. This partnership enables pharmaceutical and medical institutions in Korea to collaboratively train AI models without exposing or transferring sensitive data.
Under the agreement, Flock’s on-chain federated learning infrastructure will connect with AIGEN Sciences’ large language model (LLM)-based drug development engine. This integration allows hospitals and research institutions to retain data ownership while securely utilizing real-world clinical and research data.
“This partnership marks a major milestone toward realizing truly decentralized AI in life sciences,” said Jiahao Sun, Co-founder and CEO of Flock. “By combining our blockchain-protected incentive layer with AIGEN Sciences’ validated drug discovery platform, we can derive high-value insights in the bio-health sector while maintaining the highest standards of privacy.”
Jaewoo Kang, CEO of AIGEN Sciences, stated, “Our mission is to accelerate the journey from idea to clinic. Flock’s privacy-preserving technology opens up access to previously unreachable datasets, enabling new collaborations with hospitals and pharmaceutical companies. We believe this will help bring better medicines to market faster.”
The technical integration will be jointly led by Zehua Cheng, Chief Scientist at Flock, and Sunkyu Kim, Head of AI Research at AIGEN Sciences. The first proof-of-concept (PoC) is scheduled for Q3 2025, with plans to present the findings at leading AI and healthcare conferences.
Flock (FLock.io) is a community-driven platform that combines federated learning with blockchain technology to build on-chain decentralized AI models. It enables secure collaboration among data owners, compute providers, and AI engineers without revealing raw data, supporting both privacy protection and universal AI applications.
AIGEN Sciences is a Seoul-based biotech company accelerating small-molecule and biologics discovery by combining LLMs with multi-omics data. Founded by researchers from Korea University, the company is backed by leading venture capital firms and is building a diversified pipeline to improve patient outcomes.
Korea Central News Net 